Korea S.E.
03:30:00 17/05/2024 am IST
5-day change
1st Jan Change
37,300
KRW
+2.05%
+9.06%
-15.80%
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021
May 06, 2021 at 11:30 am IST
Hanall Biopharma Co.,Ltd announced earnings results for the first quarter ended March 31, 2021. For the quarter, the company reported sales of KRW 27.8 million compared to KRW 22.1 million a year ago. Operating Profit was KRW 5.4 million compared to KRW 3.0 million a year ago. Net income was KRW 4.5 million compared to KRW 4.0 million a year ago.
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
03/05
CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
06/03
CI
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd
12/23/12
CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.
13/23/13
CI
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.
10/23/10
CI
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
11/22/11
CI
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner
04/22/04
CI
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.
15/22/15
CI
Hanall Biopharma Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 519,451 shares, representing 1.01% for KRW 10,000.02 million.
10/22/10
CI
Turn Biotechnologies, Inc. announced that it has received funding from Astellas Venture Management LLC, Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd and other investors
12/22/12
CI
Hanall Biopharma Co.,Ltd announces an Equity Buyback for 543,479 shares.
10/22/10
CI
Hanall Biopharma Co.,Ltd authorizes a Buyback Plan.
10/22/10
CI
Alloplex Biotherapeutics, Inc. announced that it has received $1 million in funding from Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd
19/21/19
CI
Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021
29/21/29
CI
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021
06/21/06
CI
HanAll Biopharma and Harbour Biomed Sign Collaboration and License Agreement for Development of Therapies in Greater China
12/17/12
CI
Biopharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate Vm202 for Non-Healing Diabetic Foot Ulcers
03/17/03
CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to KOSPI 200 Index
10/16/10
CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index
01/15/01
CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) added to Russell Global Index
29/15/29
CI
Daewoong Pharmaceutical Co., Ltd. acquired 14.92% stake in HanAll Biopharma Co., Ltd. from Byung-Tae Kim, Sung-Soo Kim, Sung-Ji Kim, Dong-Shin Shin, and Hyun-Soo Kim for KRW 48 billion.
29/15/29
CI
Hanall Biopharma Co., Ltd. Announces Earnings Results for the First Half of Fiscal Year of 2014
26/14/26
CI
Kim Hong Cheol and two related parties acquired 5.3% stake in HanAll Biopharma Co., Ltd..
30/14/30
CI
HanAll Biopharma Co., Ltd.(KOSE:A009420) dropped from KOSPI 200 Index
17/14/17
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.
More about the company
Last Close Price
37,300
KRW
Average target price
43,600
KRW
Spread / Average Target
+16.89%
Consensus
1st Jan change
Capi.
-15.80% 1.38B +32.09% 694B +29.39% 593B -1.34% 371B +20.34% 331B +7.39% 290B +14.25% 239B -3.03% 209B +10.02% 209B +8.49% 169B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HANALL BIOPHARMA CO., LTD. 
